Latest news with #Carisma
Malaysian Reserve
10 hours ago
- Business
- Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, GNTY on Behalf of Shareholders
NEW YORK, June 27, 2025 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Carisma Therapeutics Inc. (NASDAQ: CARM)'s merger with OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company. If you are a Carisma shareholder, click here to learn more about your legal rights and options. Enzo Biochem, Inc. (OTCMKTS: ENZB)'s sale to Battery Ventures for $0.70 per share in cash. If you are an Enzo shareholder, click here to learn more about your rights and options. Guaranty Bancshares, Inc. (NYSE: GNTY)'s sale to Glacier Bancorp, Inc. for 1.0000 share of Glacier stock for each Guaranty share (subject to adjustment under certain circumstances). If you are a Guaranty shareholder, click here to learn more about your rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@ or zhalper@ Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:Halper Sadeh LLCDaniel Sadeh, Halper, Esq.(212) 763-0060sadeh@
Yahoo
4 days ago
- Business
- Yahoo
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the development of OrthoCellix's NeoCart technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration-endorsed Phase 3 clinical trial for NeoCart. OrthoCellix is developing NeoCart as an autologous cartilage implant technology utilizing patient cells to repair articular cartilage defects of the knee. The novel platform merges a fortified 3D scaffold and patented bioprocessing technology to grow chondrocytes-the cells responsible for maintaining cartilage health-to produce adolescent-like cartilage at the time of implant. NeoCart has the potential to accelerate healing and reduce pain by creating a similar, functional joint surface to help patients return to normal activities and prevent complications associated with articular cartilage damage. OrthoCellix anticipates launching its Phase 3 clinical trial by the end of 2025. Previously, NeoCart received Regenerative Medicine Advanced Therapy designation and concurrence from the FDA on a single, confirmatory Phase 3 clinical trial to enable submission of a Biologics License Application. Under the terms of the merger agreement, OrthoCellix will merge with and into a wholly-owned subsidiary of Carisma, with OrthoCellix continuing as a wholly-owned subsidiary of Carisma and the surviving company of the Merger. Carisma will issue to the pre-merger OrthoCellix stockholder shares of Carisma common stock as merger consideration in exchange for the cancellation of shares of capital stock of OrthoCellix. Carisma also expects to enter into subscription agreements for a private financing with Ocugen and other select investors, which is expected to close concurrently with the completion of the merger, to enable the combined company to complete the Phase 3 trial of NeoCart without any additional cost or investment from Ocugen. In connection with the closing of the proposed transactions, Carisma stockholders will be issued contingent value rights representing the right to receive certain payments from proceeds received by the combined company, if any, related to Carisma's pre-transaction legacy assets. Under the terms of the merger agreement, upon the closing of the proposed transactions and after giving effect to the contemplated $25M concurrent financing, OrthoCellix's stockholder and the other participants in the concurrent financing are expected to own approximately 90% of the combined company, and existing Carisma stockholders are expected to own approximately 10% of the combined company, each on a fully diluted basis. The percentage of the combined company that each company's former stockholders will own after completion of the merger is subject to adjustment based on Carisma's net cash at the closing and the proceeds from the concurrent financing, among other adjustments, in each case as described in the merger agreement. Upon the closing of the proposed transactions, 'Carisma Therapeutics Inc.' is expected to be renamed 'OrthoCellix, Inc.' and trade on the Nasdaq Capital Market under the ticker symbol 'OCLX.' The transaction has been unanimously approved by the board of directors of both companies and is expected to close in the second half of 2025, subject to customary closing conditions, including approvals by the stockholders of each company and the effectiveness of a registration statement to be filed with the Securities and Exchange Commission to register the shares of Carisma common stock to be issued in connection with the merger. In connection with the companies' entry into the merger agreement, directors and officers of Carisma and OrthoCellix's stockholder have executed support agreements, pursuant to which they have agreed to vote all of their shares of capital stock in favor of the merger or the issuance of Carisma equity in the merger, as applicable. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
NDTV
19-06-2025
- Health
- NDTV
Are Potatoes Good Or Bad For Diabetics? An Expert Says This...
Potatoes are among the most widely consumed vegetables globally. They can also be cooked in a myriad of ways, making them super versatile. Whether you prefer them boiled, fried, roasted or baked - they taste delicious in all these forms. While potatoes are a go-to for many of us, some avoid them completely, thinking they're not healthy. Diabetics are especially particular, as they fear that eating potatoes can cause a spike in their blood sugar levels. But is this really true? Should you exclude the humble potato entirely from your diet? Recently, nutritionist Amita Gadre took to her Instagram page to reveal the truth and clear the confusion once and for all. Also Read: Diabetes Diet: 6 Diabetic-Friendly Sabzis You Can Make For A Hearty Lunch Can A Diabetic Eat Potatoes? So, now the question arises: can potatoes be a part of a diabetes diet? Amita explains that potatoes contain complex carbohydrates, but they primarily consist of starch, which gets digested quickly. Whether you enjoy them boiled, par-boiled, fried or in any other form, the starch in them breaks down rapidly, causing a spike in blood sugar levels. Due to this reason, she recommends diabetics avoid or limit their intake of potatoes. What's The Healthiest Way To Consume Potatoes? The healthiest way to enjoy potatoes is by baking, roasting, par-boiling or boiling them. These methods help preserve their nutrients and avoid adding unhealthy fats. However, this doesn't mean they won't cause any spikes in your blood sugar levels. According to the nutritionist, the basic nature of starch persists even if you use a healthy cooking method. To prevent spikes in blood sugar, she suggests pairing potatoes with vegetables or a source of protein. Check out the full video below: View this post on Instagram A post shared by Amita Gadre | Nutritionist (@amitagadre) Which Potatoes Are Best For Diabetes? The market is filled with different varieties of potatoes, and deciding which one is the best option for you can be tricky. For diabetics, sweet potatoes and waxy potatoes like Carisma and Nicola are considered better choices. They have a lower glycaemic index (GI) and contain less starch compared to white potatoes like Russet. How To Make Potatoes Insulin Resistant? To make potatoes more suitable for insulin resistance, opt for baking, boiling or roasting instead of frying, and pair potatoes with protein-rich foods or veggies to balance out carbs. Eating smaller portions and adding herbs and spices for flavour can also help manage carb intake and make potatoes a part of an insulin-resistant diet. Also Read: Diabetics can still enjoy potatoes by being smart about the type, amount and cooking method.
Yahoo
19-02-2025
- Business
- Yahoo
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
PHILADELPHIA, Feb. 19, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event. About Carisma Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit Investors:Shveta Digheinvestors@ Media Contact:Julia Stern(763) 350-5223jstern@ View original content to download multimedia: SOURCE Carisma Therapeutics Inc.
